US-based development-stage biopharmaceutical firm Sorrento Therapeutics has acquired Sherrington Pharmaceuticals (Sherrington), a company that provides chronic pain treatment for end-stage cancer patients and other severe pain indications. ...
Tags: Drug, Chronic Pain Treatment
Cornerstone Pharmaceuticals has received the US Food and Drug Administration (FDA) orphan drug designation for its altered energy metabolism directed (AEMD) drug candidate 'CPI-613' for treatment of myelodysplastic syndrome (MDS). MDS is ...
Biopharmaceutical company Trigemina will deliver clinical data on its drug candidate TI-001 for the treatment of chronic migraine at the ongoing 7th Annual Pain Therapeutics Summit East in Boston, Massachusetts. The presentation will ...
Tags: Migraine Drug, Medicine
Can-Fite BioPharma, the parent company of OphthaliX, received a patent entitled ‘Adenosine A3 receptor agonists for the treatment of dry eye disorders including Sjogren’s syndrome’ from the European Patent Office. The ...
Tags: Can-Fite BioPharma
The European Commission has granted additional indication for GlaxoSmithKline’s (GSK) Tyverb (lapatinib) in combination with trastuzumab for adult patients with overexpress HER2 (ErbB2), with hormone receptor-negative (HR-) metastatic ...
Tags: European Commission
Clinical stage biopharma company Rexahn Pharmaceuticals has entered into an exclusive licensing agreement with the University of Maryland, Baltimore (UMB), for a novel drug delivery platform, which targets the delivery of chemotherapeutic ...
Tags: Rexahn Pharma, Oncology Drug
Norwegian cardiovascular biopharma Serodus has signed a merger agreement with Danish peptide specialist Phlogo to expand cardiovascular drug candidate portfolio. Subject to approval by an EGM, the merger is expected to accelerate Serodus' ...
US-based Johnson & Johnson has agreed to buy Aragon Pharmaceuticals, a discovery and development company focused on drugs to treat hormonally-driven cancers, for nearly $1bn. As per the acquisition agreeement, an upfront cash payment of ...
Tags: Johnson&Johnson, Medicine
AstraZeneca has agreed to purchase California-based respiratory medication developer, Pearl Therapeutics, in a deal with a total potential cost of up to $1.15bn. As per the definitive agreement signed between both the parties, AstraZeneca ...
Tags: AstraZeneca, Pearl Therapeutics
The US Patent and Trademark Office (USPTO) has granted a patent to GenSpera for the activation of peptide prodrugs by HK2, which is an enzyme secreted by prostate cancer cells. Composition of a series of prodrugs activated by HK2 enzyme ...
Tags: Peptide Prodrugs, Medicine
The FDA has cleared Celgene's supplemental new drug application (sNDA) for Revlimid (lenalidomide) for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL). The approval follows positive data from MCL-001 phase ...
US-based biopharmaceutical company Acadia Pharmaceuticals's glaucoma collaboration partner Allergan has advanced a new additional drug candidate into preclinical development for the treatment of glaucoma. Acadia CEO Uli Hacksell said that ...
Tags: Preclinical Development, Allergan
Danish biotechnology company Zealand Pharma and partner, the Swiss pharma group Helsinn have jointly cHelsinn's Phase IIa study with elsiglutide for the prevention of chemotherapy-induced diarrhea in cancer patients has been completed with ...
Tags: Health, Medicine, biotechnology
Canada-based pharmaceutical company Nuvo Research has received US Patent relating to compositions and methods of using WF10 and new derivative formulations for the treatment of allergic asthma, allergic rhinitis and atopic dermatitis. ...
Tags: Nuvo Research, Drug Candidate
Nimbus Discovery, a US-based biotechnology company, has entered into a co-development agreement with Shire aiming at small molecule treatments for lysosomal storage disorders (LSDs), which are considered as the rare genetic diseases. The ...